Antisense Therapeutics (ASX:ANP) closes in on clinical supplies for muscular dystrophy trial
- Antisense Therapeutics (ANP) has moved a step closer towards manufacturing the first batch of clinical supplies for its muscular dystrophy treatment clinical trial
- Through its North American supply chain, the ASX-lister has been able to formulate ATL1102's active pharmaceutical ingredient, API, into an injectable product for use in clinical trials
- The product is currently undergoing finished product release testing for clinical use, with results anticipated next month according to ANP
- The drug is hoped to aid non-ambulant Duchenne muscular dystrophy patients by targeting inflammation that aggravates muscle fibre damage
- Antisense Therapeutics shares are up five per cent following the announcement, trading at 21 cents
http://themarketherald.com.au/antisense-therapeutics-asxanp-closes-in-on-clinical-supplies-for-muscular-dystrophy-trial-2021-05-26/?utm_source=threadview%20tmh%20widget&utm_medium=widget&utm_campaign=threadview%20tmh%20widget%20%7C%20click&utm_content=https://hotcopper.com.au/threads/widely-fully-financed-companies.5271206/page-18#post-53416677&utm_term=blank
Where others have failed will Atl1102 succeed ?, page-199
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $121.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 35714 | 14.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.8¢ | 37037 | 1 |
View Market Depth
| Last trade - 16.12pm 17/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |
Day chart unavailable